New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 3, 2013
10:25 EDTOMEDOncoMed signs transformational deal with Celgene, says Piper Jaffray
Piper Jaffray says OncoMed's (OMED) deal with Celgene (CELG) is transformational that validates the company's demcizumab. The firm reiterates an Overweight rating on OncoMed, saying it will evaluate its $30 price target following the news.
News For OMED From The Last 14 Days
Check below for free stories on OMED the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for OMED

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use